Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCOVID
- Development stage
- Discontinued
- Lead developer
- Altimmune
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intranasal
01
Overview
AdCOVID is a single-dose intranasal vaccine candidate developed by Altimmune for the prevention of COVID-19. It is based on an adenoviral vector platform and was designed to stimulate both systemic (serum-neutralizing antibody, T cell) and local mucosal immunity (IgA antibodies, resident memory T cells) in the respiratory tract against SARS-CoV-2. Preclinical studies demonstrated robust immune responses and protection in animal models. The vaccine aimed to offer advantages such as needle-free administration, potential for blocking transmission, and extended room temperature stability. Despite promising early data, development of AdCOVID has been discontinued.
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on AdCOVID.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCOVID.